Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli," Monaldi Hospital, Naples, Italy.
Departments of Cardiology; and.
J Cardiovasc Pharmacol. 2020 Aug;76(2):138-145. doi: 10.1097/FJC.0000000000000854.
Coronavirus disease 2019 (COVID-19) outbreak is a public health emergency of international concerns because of a highly pathogenic human coronavirus (HCoV), actually named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite much emerging data about the epidemiological association between cardiovascular diseases and COVID-19, little is still known about atrial fibrillation and its optimal management in this clinical contest. The aim of our review is to describe the pharmacological interactions between cardiovascular drugs more commonly used in atrial fibrillation management and experimental COVID-19 therapies, based on EU and US summaries of product characteristics.
2019 年冠状病毒病（COVID-19）疫情是国际关注的公共卫生紧急事件，原因是一种高致病性人类冠状病毒（HCoV），实际上被命名为严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）。尽管关于心血管疾病与 COVID-19 之间的流行病学关联有大量新出现的数据，但在这种临床情况下，对心房颤动及其最佳管理仍知之甚少。我们的综述旨在根据欧盟和美国产品特性摘要，描述在心房颤动管理中更常用的心血管药物与实验性 COVID-19 疗法之间的药物相互作用。
